Ontology type: schema:ScholarlyArticle
2013-08-10
AUTHORSJudith Neukirchen, Uwe Platzbecker, Katja Sockel, Antonis Tsamaloukas, Rainer Haas, Ulrich Germing
ABSTRACTImmunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5 % and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60 %); three patients achieved a complete remission 3 and 6 months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10 days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated. More... »
PAGES65-69
http://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1
DOIhttp://dx.doi.org/10.1007/s00277-013-1859-1
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1046839559
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/23934199
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Alemtuzumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal, Humanized",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antigens, CD",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antigens, Neoplasm",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Blood Component Transfusion",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Marrow",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "CD52 Antigen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cell Count",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Combined Modality Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "DNA (Cytosine-5-)-Methyltransferases",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "DNA Methyltransferase 3A",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Evaluation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Glycoproteins",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Immunosuppressive Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Injections, Intravenous",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Injections, Subcutaneous",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Myelodysplastic Syndromes",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Remission Induction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Neukirchen",
"givenName": "Judith",
"id": "sg:person.0643404664.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany",
"id": "http://www.grid.ac/institutes/grid.412282.f",
"name": [
"Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany"
],
"type": "Organization"
},
"familyName": "Platzbecker",
"givenName": "Uwe",
"id": "sg:person.0670313557.25",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany",
"id": "http://www.grid.ac/institutes/grid.412282.f",
"name": [
"Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany"
],
"type": "Organization"
},
"familyName": "Sockel",
"givenName": "Katja",
"id": "sg:person.01040552530.23",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040552530.23"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Private Practice, Hilden, Germany",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Private Practice, Hilden, Germany"
],
"type": "Organization"
},
"familyName": "Tsamaloukas",
"givenName": "Antonis",
"id": "sg:person.01002544733.03",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002544733.03"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Haas",
"givenName": "Rainer",
"id": "sg:person.01127414674.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Germing",
"givenName": "Ulrich",
"id": "sg:person.01362464041.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.onc.1210380",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035428201",
"https://doi.org/10.1038/sj.onc.1210380"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2011.44",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023546509",
"https://doi.org/10.1038/leu.2011.44"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.leu.2403239",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015449707",
"https://doi.org/10.1038/sj.leu.2403239"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.leu.2404747",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011177675",
"https://doi.org/10.1038/sj.leu.2404747"
],
"type": "CreativeWork"
}
],
"datePublished": "2013-08-10",
"datePublishedReg": "2013-08-10",
"description": "Immunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5\u00a0% and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60\u00a0%); three patients achieved a complete remission 3 and 6\u00a0months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10\u00a0days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated.",
"genre": "article",
"id": "sg:pub.10.1007/s00277-013-1859-1",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1358129",
"issn": [
"0939-5555",
"1432-0584"
],
"name": "Annals of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "93"
}
],
"keywords": [
"hypocellular bone marrow",
"bone marrow",
"low-risk myelodysplastic syndrome patients",
"CD52 antibody alemtuzumab",
"complete remission 3",
"myelodysplastic syndrome patients",
"standard treatment protocol",
"lower-risk MDS",
"severe side effects",
"long-term survival",
"RCMD patients",
"remission 3",
"alemtuzumab treatment",
"immunosuppressive therapy",
"blast count",
"haematological improvement",
"antibody alemtuzumab",
"therapeutic options",
"MDS patients",
"MDS treatment",
"syndrome patients",
"treatment protocol",
"alemtuzumab",
"side effects",
"patients",
"Further studies",
"treatment",
"marrow",
"real-life experience",
"IPSS",
"therapy",
"progression",
"months",
"efficacy",
"CsA",
"promising results",
"survival",
"risk",
"count",
"dosage",
"days",
"life experiences",
"options",
"experience",
"findings",
"response",
"study",
"protocol",
"MD",
"ATG",
"effect",
"improvement",
"regard",
"results"
],
"name": "Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow",
"pagination": "65-69",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1046839559"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00277-013-1859-1"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"23934199"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00277-013-1859-1",
"https://app.dimensions.ai/details/publication/pub.1046839559"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:00",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_587.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00277-013-1859-1"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'
This table displays all metadata directly associated to this object as RDF triples.
276 TRIPLES
21 PREDICATES
109 URIs
97 LITERALS
33 BLANK NODES